| [1] |
Aragon-Ching JB, Zujewski JA. CNS metastasis: an old problem in a new guise[J]. Clin Cancer Res, 2007, 13(6): 1644-7.
|
| [2] |
Hohensee I, Lamszus K, Riethdorf S, et al. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases[J]. Am J Pathol, 2013, 183(1): 83-95.
|
| [3] |
Arslan C, Dizdar O, Altundag K. Systemic treatment in breast-cancer patients with brain metastasis[J]. Expert Opin Pharmacother, 2010, 11(7): 1089-100.
|
| [4] |
Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets[J]. Nat Rev Cancer, 2011, 11 (5): 352-63.
|
| [5] |
Zhang L, Sullivan PS, Goodman JC, et al. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase[J]. Cancer Res, 2011, 71(3): 645-54.
|
| [6] |
Rama k r i s h n a N, Temi n S, Ch a n d a r l a p a t y S, e t a l . Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2014, 32 (19): 2100-8.
|
| [7] |
Bartsch R, Berghoff A, Pluschnig U, et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases[J]. Br J Cancer, 2012, 106(1): 25 -31.
|
| [8] |
Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER[J]. Clin Cancer Res, 2011, 17(14): 4834-43.
|
| [9] |
Witzel I, Kantelhardt EJ, Milde-Langosch K, et al. Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer[J]. Onkologie, 2011, 34(6): 304-8.
|
| [10] |
Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial(BIG 1-01)[J]. Lancet Oncol, 2013, 14(3): 24 4-8.
|
| [11] |
Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease[J]. Pharmacol Rev, 2005, 57(2): 173-85.
|
| [12] |
Pestalozzi BC, Brignoli S. Trastuzumab in CSF[J]. J Clin Oncol, 20 00, 18(11): 2349-51.
|
| [13] |
Zagouri F, Sergentanis TN, Bartsch R, et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis[J]. Breast Cancer Res Treat, 2013, 139(1): 13-22.
|
| [14] |
Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine[J]. Ann Oncol, 2011, 22 (3): 625-30.
|
| [15] |
Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study[J]. Lancet Oncol, 2013, 14(1): 64-71.
|
| [16] |
Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer[J]. Pharm Res, 2012, 29(3): 770-81.
|
| [17] |
Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}- 6- [5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4 -quinazolinamine (GW572016, lapatinib) disposition and drug interactions[J]. Drug Metab Dispos, 2008, 36(4): 695-701.
|
下载:
